Intensive glucose control and cardiovascular disease in type 2 diabetes - Should we change the recommended target for glycated hemoglobin? Commentary to ACCORD and ADVANCE trials

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 11, 2008, Pages 619-621

  Gæede, Peter ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLICLAZIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INCRETIN; INSULIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETIC RETINOPATHY; EDITORIAL; GLYCEMIC CONTROL; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RISK REDUCTION; STROKE;

EID: 57149098241     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (13)

1. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. New Engl J Med. 2008; 358: 2545-2559.
2. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. New Engl J Med. 2008; 358: 2560-2572.
3. UKPDS 35. Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes: prospective observational study. BMJ. 2000; 321: 405-412.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356: 2457-2471.
5. Lawson P, Champion M, Canny C, et al. Continuous subcutaneous insulin infusion does not prevent progression of preproliferative or proliferative retinopathy. Br J Ophtalmol. 1982; 96: 762-766.
6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329: 977-986.
7. Bloomgarden ZT. Glycemic control in diabetes: a tale of three stories. Diabetes Care. 2008; 31: 1913-1919.
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
9. Gæde P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999; 353: 617-622.
10. Gæde P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Eng J Med. 2003; 348: 383-393.
11. Gæde P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008; 358: 580-591.
12. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005.
13. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Eur Heart J. 2007; 28: 88-136.